Evidence map›Paper›PMID 25808322›Full record

ArticleExperimental dermatology2015

Metastasis suppressor NME1 regulates melanoma cell morphology, self-adhesion and motility via induction of fibronectin expression.

Marián Novak, Mary Kathryn Leonard, Xiuwei H Yang, Anjan Kowluru, Alexey M Belkin, David M Kaetzel

Open access · hybridAbstract read
In one paragraph

Article in Experimental dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. NM23/NDPK proteins in transcription regulatory functions and chromatin modulation: emerging trends.Laboratory investigation; a journal of technical methods and pathology · 2018
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Marián NovakDepartment of Biochemistry and Molecular Biology, Greenebaum Cancer Center, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
Mary Kathryn LeonardDepartment of Biochemistry and Molecular Biology, Greenebaum Cancer Center, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
Xiuwei H YangDepartment of Molecular and Biomedical Pharmacology, College of Medicine, University of Kentucky, Lexington, KY, USA.
Anjan KowluruDepartment of Pharmaceutical Sciences, John D. Dingell VA Medical Center, Wayne State University, Detroit, MI, USA.
Alexey M BelkinDepartment of Biochemistry and Molecular Biology, Greenebaum Cancer Center, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
David M KaetzelDepartment of Biochemistry and Molecular Biology, Greenebaum Cancer Center, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
University of Maryland, Baltimore · USUniversity of Kentucky · USWayne State University · US

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Suppression of Melanoma Initiation and Progression by NM23-H1R01CA159871 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KAETZEL, DAVID M · 2012 to 2016
$2.2M
NM23 PROTEINS AND MECHANISMS OF PDGF A CHAIN SILENCINGR01CA083237 · NCI · UNIVERSITY OF KENTUCKY · PI KAETZEL, DAVID M · 1999 to 2010
$1.9M
NCI NIH HHS CA159871NCI NIH HHS CA83237NCI NIH HHS P30 CA134274NCI NIH HHS R01 CA083237NCI NIH HHS R01 CA159871NCI NIH HHS T32 CA154274NCI NIH HHS T32CA15474
6 · The paper itself

Abstract

Expression of the metastasis suppressor NME1 in melanoma is associated with reduced cellular motility and invasion in vitro and metastasis in vivo, but the underlying molecular mechanisms are not completely understood. Herein, we report a novel mechanism through which NME1 controls melanoma cell morphology via upregulation of the extracellular matrix (ECM) protein fibronectin. Expression of NME1 strongly suppressed cell motility in melanoma cell lines 1205LU and M14. The resulting sedentary phenotype was associated with a more flattened appearance and marked increases in actin stress fibre and focal adhesion formation. NME1-induced focal adhesions were colocalized with dense deposits of fibronectin, which were absent or minimal in the corresponding NME1-deficient parental lines. NME1 was a strong inducer of fibronectin mRNA and protein expression, shown with reciprocal approaches of forced NME1 expression and shRNA-mediated knock-down. Increased synthesis and ECM deposition of fibronectin was necessary for NME1-induced cell spreading, as knock-down of fibronectin opposed the effects of NME1 on cell morphology. Fibronectin knock-down also reversed the ability of NME1 to promote aggregation when cells were plated on a non-adherent substratum. Similarly, inhibiting activation of the fibronectin receptor integrin α4β1 with an anti-α4 antibody reversed the motility-suppressing effect of NME1. A positive correlation was observed between NME1 and fibronectin mRNA in clinical biopsies of normal skin, benign nevi and primary melanomas, but not in metastatic forms, suggesting the NME1/fibronectin axis represents a barrier to melanoma progression. In summary, these findings indicate fibronectin is an important effector of the motility-suppressing function of NME1 in melanoma cells.

Indexed as

Cell AdhesionCell Line, TumorCell MovementDisease ProgressionExtracellular MatrixFibronectinsGene Expression Regulation, NeoplasticHumansIn Vitro TechniquesMelanomaNeoplasm MetastasisNM23 Nucleoside Diphosphate KinasesRNA, MessengerSignal TransductionSkin NeoplasmsFibronectinsNM23 Nucleoside Diphosphate KinasesNME1 protein, humanRNA, MessengerfibronectinmelanomamotilityNME1

Identifiers

PMID25808322
PMCPMC4437809
OpenAlexW2046842139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.